Xinnate

Mariposa Therapeutics

This biotechnology company develops a topical small-molecule therapy for patients with the rare genetic skin condition epidermolysis bullosa simplex.

BioMendics

BioMendics develops liquid crystal small molecule therapeutics for patients suffering from rare genetic dermatologic disorders such as epidermolysis bullosa simplex.

ChainPeptides

This company develops synthetic antimicrobial peptides to treat chronic wounds and combat multi-drug resistant bacterial infections for healthcare providers and patients.

DermBiont

This clinical-stage biotechnology company develops targeted topical therapeutics to treat skin diseases, such as hyperpigmentation and seborrheic keratoses, for patients with dermatological conditions.

Castle Creek Biosciences

This company develops cell and gene therapies for patients suffering from rare genetic skin and connective tissue diseases.

Krystal Biotech

This biotechnology company develops and commercialises redosable gene therapies for patients with rare genetic diseases, including dystrophic epidermolysis bullosa.

Arcutis Biotherapeutics

This biopharmaceutical company develops and commercialises topical treatments for patients with chronic inflammatory skin diseases such as psoriasis, eczema, and seborrhoeic dermatitis.

PinCell

This biotechnology company develops anti-inflammatory therapies and monoclonal antibodies for patients suffering from rare and severe skin diseases.